--FDA Grants Pre-BLA Meeting Request and Rolling BLA Submission after Review of HOPE-2 and HOPE-2 OLE 3-Year Results-- SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (CAPR) (NASDAQ ...

Capricor Therapeutics Inc. (NASDAQ:CAPR) is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like Duchenne muscular dystrophy (DMD). Capricor's stock ...

We came across a bearish thesis on Capricor Therapeutics, Inc. on Alpha Talon Investment Research’s Substack by AT Investment ...

-Company Plans to Complete Rolling BLA Submission by End of 2024; Application May be Eligible for Priority Review by FDA- SAN DIEGO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: ...

BLA submission of deramiocel for treatment of patients with DMD cardiomyopathy is expected in October 2024, with the completed portion expected before the end of 2024. The Duchenne Muscular Dystrophy ...

Capricor Therapeutics announced positive results from the four-year HOPE-2 Open-Label Extension study for their lead cell therapy candidate, Deramiocel, aimed at treating Duchenne Muscular Dystrophy ...

Milestone represents a significant step forward in the development of deramiocel for the treatment of Duchenne muscular dystrophy in the European region SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- ...

FDA has indicated that an Advisory Committee meeting is not required at this time In-person late-cycle review meeting scheduled for mid-July Biologics License Application (BLA) remains under Priority ...

–Publication highlights Deramiocel’s anti-fibrotic activity and describes a validated potency assay supporting quality control and product consistency in late-stage development– SAN DIEGO, Nov. 03, ...

One of the best Russell 2000 stocks, Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a biotechnology company dedicated to developing innovative cell and exosome-based therapies. They are aimed at ...

SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare ...